This work proposes a two-dimensional clinical framework for negative symptoms to better understand their neurobiological mechanism, by segregating symptoms into diminished expressivity and amotivation domains and explores how biological sex serves as a critical factor of individual variability in symptom expression.
Abstract
Negative symptoms represent a debilitating core of schizophrenia symptomatology that fail to respond to treatment with D2 antagonist antipsychotic drugs and may even be exacerbated by D2 antagonism. The neurobiological mechanisms underlying these symptoms are proposed to be related to limbic hippocampal hyperactivity, which is associated with the loss of parvalbumin-expressing GABAergic interneurons. This hippocampal hyperexcitability generates aberrant excitatory and dysrhythmic output to key limbic regions. Dysregulation of limbic hippocampal projections to the ventral striatum could impair reward processing, while disrupted connectivity with the prefrontal cortex and amygdala may underlie deficits in motivation, effort-based decision-making, and social behavior. We propose a two-dimensional clinical framework for negative symptoms to better understand their neurobiological mechanism, by segregating symptoms into diminished expressivity and amotivation domains. We also explore how biological sex serves as a critical factor of individual variability in symptom expression. For instance, males tend to have greater social withdrawal and avoidance, while females often show vulnerability to affect and mood disturbances. Understanding these circuit-level pathologies offers a mechanistic basis for the development of emerging treatments, such as GABAergic modulators, glutamatergic agents, and muscarinic agonists, which aim to restore normal hippocampal excitability. A dimensional, biomarker-informed approach could advance the development of personalized therapeutic strategies and ultimately improve functional outcomes for individuals living with schizophrenia.
This review argues that TRN dysfunction may help explain how cellular abnormalities, sleep-spindle deficits, thalamocortical dysconnectivity, and clinical symptoms become linked across the psychosis spectrum and proposes a stage-dependent model in which early TRN dysfunction contributes to subtle sensory and cognitive...
P. Seif· Neuroscience and Biobehavior...· 0 citations
A mechanistic framework in which CRF-mediated recruitment of hypothalamic OX neurons contributes to neuroplasticity deficits in the mPFC, HIPP, and AMY is proposed, which positions OX transmission as a potential link between chronic stress and mood-related psychopathology.
Alexa C. E. Alcala, Sophia C. Bellitire, Katherine Brunson et al.· Frontiers in Psychiatry· 0 citations
It is indicated that stereochemical and subunit-selective modulation of GABAA receptors critically determines circuit-level outcomes following stress and reinforce α5-GABAA receptors as a key target for normalizing hippocampal-driven dopamine system dysfunction associated with psychosis-relevant states.
Kayla Lilly, Prithu Mondal, James M. Cook et al.· Psychopharmacology· 1 citation
Psychedelics (hallucinogenic 5-HT2A agonists such as psilocybin) are being investigated for their potential to treat a range of conditions, including anxiety-related psychopathology. Despite promising results, the mechanisms by which psychedelic therapy may alleviate anxiety are not well understood. Here, we review neu...
Hugh Mcgovern, Nick Wellman, B. Hutchinson et al.· Psychopharmacology· 1 citation
Social cognition, essential for interpreting and responding to social contexts, is frequently impaired in neurological and psychiatric disorders. Multiple brain regions, organized in large-scale brain networks, represent the neurobiological substrate of social cognitive abilities, and are the main target of neurodegene...